| Home
|
Chiron Corp., with headquarters in Emeryville, California, delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives.
Oct. 31, 2005 | Chiron Corporation (NASDAQ:CHIR) today
announced that it has entered into a definitive merger agreement with
Novartis under which Novartis will acquire all of the shares of Chiron
that it does not currently own. Novartis will acquire approximately 113
million Chiron shares, or 58 percent of all Chiron shares, for $45.00
per Chiron share, or a total of approximately $5.1 billion, in cash. |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| HISTORY | TYPE | Divestiture / Closures of Businesses |
| Dec 8, 2005 | TC | Sale of $300 million in newly issued shares of its common stock at a price of $43.50 per share to a subsidiary of Novartis - Under provisions of the 1994 Subscription Agreement with Novartis, as amended, Chiron exercised its right on October 30, 2005, to have Novartis purchase the newly issued shares. |
| HISTORY | TYPE | Acquisitions / Strategic Investment |
| Oct 31, 2004 |
TC TND |
Prion Solutions Inc., a privately held company based in La Jolla, Calif., focused on research into variant Creutzfeldt-Jakob disease (vCJD) and other prion-related diseases. | Linked to: |
| Jul 6, 2004 |
TC TND |
Sagres Discovery, a privately held company headquartered in Davis, Calif., focuses on the discovery and validation of targets with potential application to the development of cancer therapeutics. | Linked to: Axiom Venture Partners; Burrill; Forward Ventures |
| May 19, 2003 | DA | PowderJect Pharmaceuticals plc, a U.K.-based vaccines company - launched a recommended cash tender offer for all outstanding ordinary shares of PowderJect, a UK-based vaccines company, at a price of 550 pence per share, or approximately $878 million in the aggregate at the time of the announcement. |
| Mar 29, 2002 | TC | Matrix Pharmaceutical Inc. (Nasdaq: MATX) for $2.21 in cash without interest per share. |
| Jan 7, 2002 | DA | Matrix Pharmaceutical Inc. (Nasdaq: MATX) to acquire the company for $61 million. | Linked to: IPOs; Canaan Partners; Menlo Ventures; Vector Fund Management |
| 2000 | PathoGenesis, a Seattle-based biotech company | Linked to: | |
| Ribozyme Pharmaceuticals | Linked to: 1996 IPOs; Advent International; Chiron; CW Group; GeneChem; Granite Global; Mortenthaler-Ventures; Oxford Bioscience; The Sprout Group; Techno Venture Management; Venrock; Whitney & Co. | ||
| 1991 | Cetus Corp., a San Francisco Bay Area biopharmaceutical company | |
| TYPE | |
| DA2A (DA2M) | Definite Agreement to Acquire (Merge) |
| DA | Definite Agreement |
| TC | Transaction Completed |
| TND | Terms of the transaction were not disclosed |
| TO | Tender offer |
Copyright 2006 © PEsource, Inc. All Rights Reserved